Detall de la convocatòria

Característiques

Característica
Objectiu de la convocatòria
Bill Gates and ADDF co-founder Leonard Lauder are partnering and adopting a new approach that brings together philanthropic capital with a venture mindset to advance bold new ideas for easier and more accurate diagnosis of Alzheimer's disease and related dementias.
Característiques principals
The current RFP is soliciting projects to develop and validate digital biomarkers for Alzheimer's disease and related dementias. Digital biomarkers are defined as objective, quantifiable physiological and behavioral data that are collected, measured and analyzed by means of digital devices such as portables, wearables, or ambient sensors. Digital biomarkers range from computerized or app-based versions of traditional neurocognitive tests to novel technology platforms that combine multiple complex data sources into a phenotypic signature.

Funding priorities:
  • Platforms: A variety of digital platforms such as portables, sensors, or software are encouraged. The proposed platform should have the potential to be easily deployed at scale.
  • Symptom Domains: The RFP encourages digital biomarkers emerging from one or more of the symptom domains below. Proposed approaches will be evaluated based on the existing evidence around the biological link of the symptom domain to disease and how measuring the proposed symptom domain will improve current screening or monitoring methods in patients.

    Three stages of projects will be supported:
  • Exploratory awards will support pilot studies that aim to test the utility of an existing digital technology for the first time in an Alzheimer's disease or related dementia population.
  • Proof-of-principle awards will support projects that demonstrate feasibility and/or verify that a certain approach has potential for use in Alzheimer's disease or related dementias.
  • Validation awards will support projects that require testing at a larger scale and access to patients of varying demographic diversity to demonstrate clinical relevance.
    • Lloc de presentació
    El personal de l'IMIM i PSMAR que necessiteu més informació adreceu-vos a:
    Servei de Recerca. C/ Doctor Aiguader, 88. 08003-Barcelona. Tel.: 93.316.05.76.
    Marta López: mlopez4@imim.es Ext.: 1576
    Carol Barnwell: cbarnwell@imim.es Ext.: 1670
    Convocatòria (URL)
    https://www.alzdiscovery.org/accelerator/digital-biomarkers-rfp
    Applications:
    https://addf.fluxx.io/
    Requisits
    Funding is open to researchers and clinicians worldwide at:
  • Academic medical centers and universities or nonprofits. Industry partnerships are strongly encouraged.
  • Biotechnology companies. Funding is provided through mission-related investments that require return on investment. Existing companies and new spinouts are both eligible.
    • Dotació
  • Exploratory awards: $250,000
  • Proof-of-principle awards: $500,000
  • Validation awards: Award amounts will be based on the stage and scope of the research.
    • AVÍS IMPORTANT
    The deadline for applications is August 16, 2019. Submission of a Letter of Intent (LOI) is required on or before June 7, 2019. LOIs are reviewed on a rolling basis and can be submitted any time prior to the deadline.

    Arxius

    Arxiu
    Diagnostics Accelerator_ Digital Biomarkers Application Instructions _ Alzheimer's Drug Discovery Foundation.pdf
    Diagnostics Accelerator_ Digital Biomarkers Body of the Application Instructions _ Alzheimer's Drug Discovery Foundation.pdf
    Funding Opportunities_ Application & Funding Policies _ Alzheimer's Drug Discovery Foundation2.pdf
    Diagnostics Accelerator_ Digital Biomarkers _ Alzheimer's Drug Discovery Foundation.pdf